# The 4th Sino-American Symposium on Clinical and Translational Medicine

**On June 22 - 23, 2013, at Beijing International Conference Center**

**Theme: Better Communication for Better Outcomes**

## PROGRAM (June 1st DRAFT)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>June 21st:</td>
<td>Registration and Pre-Conference Meeting hosted by &lt;Translational Medicine Journal&gt;:</td>
</tr>
<tr>
<td>15:00-17:30</td>
<td>Get together to share the experiences to visit the USA NIH Clinical Center, Yale YCCI and Duke CTSI</td>
</tr>
<tr>
<td>June 22nd (Saturday):</td>
<td></td>
</tr>
<tr>
<td>MORNING:</td>
<td>Opening remarks by co-chairmen for the 4th SAS-CTM</td>
</tr>
<tr>
<td>8:00-8:30</td>
<td>Welcome by local organizer, Dr. QIAN Yangming, Editor-in-Chief for Translational Medicine Journal</td>
</tr>
<tr>
<td></td>
<td>Clinical and Translational Medicine Fund: Physician-Scientist Awards by Global MD Org. and Chinese Medical Association (CMA), Chinese International Medical Foundation (CIMF)</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Plenary Session 1:</td>
<td>Better Communication for Better Outcomes in Translational Research Collaboration</td>
</tr>
<tr>
<td>Co-chairs:</td>
<td>Professor DAI Jianping and Dr. Barbara Alving</td>
</tr>
<tr>
<td>8:30-8:55</td>
<td>Keynote Speech 1: From Government Grants to Private Fund: the Landscape Changing to Support Clinical and Translational Research</td>
</tr>
<tr>
<td></td>
<td>Professor DAI Jianping, Vice Chair of Chinese Medical Association, Director for China International Medical Foundation, the member of Institute of Medicine (IOM), the U.S.</td>
</tr>
<tr>
<td>8:55-9:20</td>
<td>Keynote Speech 2: NIH-CTSA funded the USA 60 CTSIs, What are the problems be solved? What are the Trends in CTS within next 5 years?</td>
</tr>
<tr>
<td></td>
<td>Dr. Barbara Alving, formerly Director of NIH NCRR, in charge of NIH CTSA program, now at Univ. of Maryland</td>
</tr>
<tr>
<td>9:20-9:45</td>
<td>Plenary Speech 3: Industrial Partner Focusing on Outcomes, Marketing Competition and Efficiency: Clinical and Translational Research Strategy and Methodology on Oncology</td>
</tr>
<tr>
<td></td>
<td>Dr. PENG Bin, Director of Novartis Cancer Drug Translational Science Center, Shanghai, China</td>
</tr>
<tr>
<td>9:45-10:15</td>
<td>Session speakers in a Panel: Communication channels needed for translational research</td>
</tr>
<tr>
<td>Moderators:</td>
<td>Dr. ZENG Yixin, Dean of Beijing Union Medical College, VP of Chinese Academy of Medical Sciences</td>
</tr>
<tr>
<td></td>
<td>Dr. York Tomita, Sr. Advisor for FDA Commissioner Office and Critical Path and Innovation Office</td>
</tr>
<tr>
<td></td>
<td><strong>Panelists:</strong> Professor DAI Jianping, Dr. Barbara Alving and Dr. PENG Bin together with two Moderators</td>
</tr>
<tr>
<td>10:15-10:30</td>
<td>Tea/coffee break</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Plenary Session 2:</td>
<td>Clinical and Translational centers for better collaboration, nationally and internationally</td>
</tr>
<tr>
<td>Co-chairs:</td>
<td>Dr. FU Xiaoabin and Dr. Anantha Shekhar</td>
</tr>
<tr>
<td>10:30-10:55</td>
<td>Plenary speech 4: Vanderbilt’s Innovation in the Clinical and Translational Research Process</td>
</tr>
<tr>
<td></td>
<td>Dr. David Robertson, Director of the Clinical Research Center at the Vanderbilt Univ. CTSA.</td>
</tr>
<tr>
<td></td>
<td>Dr. Xiaobing Fu, Director for the Center of Translational Research at PLA General Hospital</td>
</tr>
<tr>
<td></td>
<td>Ms. LU Jun, Vice Chairman for Chinese Physician Association,</td>
</tr>
<tr>
<td></td>
<td>Dr. LIU Qilin, Director for Training Division at Chinese Physician Association</td>
</tr>
<tr>
<td>11:45-12:10</td>
<td>Plenary speech 7: Developing a Statewide Translational Research Program</td>
</tr>
<tr>
<td></td>
<td>Dr. Anantha Shekhar, Chairman for the Association of Clinical and Translational Sciences</td>
</tr>
<tr>
<td></td>
<td>Sr. Associate Dean and Director of Clinical and Translational Science Institute, University of Indiana</td>
</tr>
<tr>
<td>12:10-12:30</td>
<td>Session speakers in a Panel: Sharing Best Practice and Methodologies</td>
</tr>
<tr>
<td>Moderators:</td>
<td>Professor ZHONG Nanshan, Director for Guangzhou Institute of Respiratory Diseases.</td>
</tr>
<tr>
<td></td>
<td>Dr. Greg Koski, Massachusetts General Hospital, President of the Society of Pharmacology and Medical Research, Professor at Harvard University.</td>
</tr>
<tr>
<td></td>
<td><strong>Panelists:</strong> Drs David Robertson, Xiaobing Fu, LIU Qilin and Anantha Shekhar, with two Moderators</td>
</tr>
<tr>
<td>12:30-13:45</td>
<td>Lunch break/sponsored lecture/private meeting</td>
</tr>
</tbody>
</table>

**Editors board meeting:** Translational Medicine Journal Editor-in-Chief, Dr. QIAN Yangming, President of Navy General Hospital Collaboration in Journals of Translational Medicine and Publication Policies

**News Book Release:** NIH Principles and Practice of Clinical Research, the 3rd ed Chinese Version, Reading and Commentary Co-chaired by Professors. WANG Jiyao, LIU Xiaqing, WANG Rui and Dr. YANG Xiaoling
AFTERNOON: Participatory Sessions (14:00 - 17:00)

Focus Group 1: Translational Research in Oncology: the Priority Subjects of Basic, Clinical and Translational Studies

Co-Chairs: Prof. WU Kaichun, Vice President of the 4th Military Medical University  
Dr. Dr. Vicki Seyfert-Margolis, formerly FDA Commissioner Office Sr. Sci. Advisor  
Dr. FENG Bing, Novartis Pharmaceutical

1) Lung Cancer and Translational Research  
2) Lung Cancer Biomarker  
3) Liver Cancer and Clinical Translational Research  
4) Therapeutic solution and Translational Research on Nasopharyngeal carcinoma  
5) Translational Research in gastrointestinal cancer  
6) Principles for Cancer Drug Clinical Trials  
7) Cancer Biomarkers: Applications and Methods  
8) FDA’s Biomarker Qualification Program:  
9) Anti-Cancer Drugs Reviewing Bottle-net issue  
10) Cellular Therapy & Translational Res. in Cancer  
11) DNA methylation based cancer diagnostics: opportunities and challenges

Focus Group 2: Stem Cell Clinical Research: Principles and Consensuses of Clinical and Translational Studies

Co-Chairs: Dr. WU Zuze, Chinese Military Academy of Medical Sciences  
Professor HAN Zhongchao, Director of China National Center of Stem Cell Research and Engineering  
Professor FU Xiaobin, Director for the Center of Translational Research at PLA General Hospital

- Stem Cell Research at Yale University- Translational View  
- Clinical research of genetically modified dendritic cells combining to Cytokine-Induced Killer cell treatment in advanced Renal Cancer  
- miRNA Sequencing in Human induced Pluripotent Stem Cell Derived Cardiomyocytes: Novel Insights into Regulatory Pathways Involved in Cardiac Hypertrophy  
- TBD

- Prof. ZENG Fanyi, Deputy Director of Genetic Diseases Research Institute, Shanghai Jiaotong Univ. School of Medicine  
- The Standards of Clinical Applications and Safety Issues  
- Clinica translatinal research about stem cells in the patients with limb ischemia

- Clinical therapy with stem cells and their transplantation in multiple diseases  
- Prof. GU Yongquan, Beijing Capital Medical University Xuan Wu Hospital

- Prof. ZHUO Guangsheng, Director of HAN Union Biotechnology Co. China  
- Prof. WU Xiaoxiong, PLA General Hospital affiliated 1st Hospital (304)

- Dr. ZHUO Guangsheng, Director of HAN Union Biotechnology Co. China
Session A: Sharing experiences on building a comprehensive center for clinical and translational medicine
Co-chaired by Dr. ZHANG Shuyang, VP of Beijing Union Hospital, Chinese Academy of Medical Sciences
Ms. Tesheia Johnson, Chief Operation Officer, Yale Center for Clinical Investigation, Yale University

1. PUMC Hospital and GCP Center as the Translational Research front line
   Professor ZHANG Shuyang, Vice President of Beijing Union Hospital and Director of PUMC Hospital GCP Center

2. Yale University Drug Clinical Trial Center – a Collaborative Mechanism of New Drug Discovery
   Dr. Richard Bucala, Director for Epidemiology and Pathology, in charge of early phase drug trial studies, Yale University

3. Chinese Hospital-based Translational Research Center: Top Design and Practice with the International HRP Standards
   Dr. LI Ning, President of Beijing YouAn Hospital, Beijing Capital Medical University

4. Hospital-GCP Center: Collaboration with Industrial Partner to Advancing Drug Clinical Trials
   Professor YUAN Hong, Vice President of the 3rd Xiangya Hospital, China Central South University

5. The Vanderbilt MSCI Program: Educating Leaders in Clinical and Translational Science
   Dr. Satish R. Raj, Director for Division of Cardiology & Clinical Pharmacology, Vanderbilt Univ. Board Member of ACTS

6. Technology and Innovation Transferring Center at West China Hospital: Advancing Research Outcomes and Demonstration
   Professor GONG Qiyong, Vice President of West China Hospital, Sichuan University School of Medicine

7. Aligned with International Standards to build up Clinical Research and Innovation Center: Focusing on Improvement of Cardiovascular Diseases Therapeutics and Medical Devices
   Professor MA Changsheng, Beijing Anzhen Hospital, Beijing Capital Medical University

8. GCP platform infrastructure and development: Provide Evidence and Recommendation for Improvement of Clinical Therapeutics and Individual Medicine
   GCP Drug Clinical Trial Center, ZheJiang Univ. affiliated the first Hospital

9. Q & A

Session B: International collaborative strategy and implementation plan for translational research
Co-chaired by: Professor GUI Yonghao, Vice Chancellor and Dean of Shanghai Med. College, Fudan University
Dr. Joseph Kolars, Sr. Associate Dean for Univ of Michigan

1. Harvard CTSI – Chinese Academic Partners on Translational Sciences: Goals and Vision
   Professor GUI Yonghao, Vice Chancellor and Dean of Shanghai Medical College, Shanghai Fudan University

2. Peking University Medical Center and Univ. of Michigan CTSI Strategic Partnership and Experience
   Dr. Joseph Kolars, Director of UM CTSI and Sr. Associate Dean for Univ. of Michigan School of Medicine

3. Duke Univ. Kunshan Campus: the first Independent Clinical Research and Training Site in China
   Robert Califf, Vice Chancellor of clinical and translational research, Duke Univ. Director for Duke CTSI

4. Zhongshan Univ. School of Medicine: Joint collaborations with the Johns Hopkins Univ. School of Medicine CTSI
   Professor LI Mengfeng, Dean of Zhongshan Medical College, Zhongshan University

5. Director for Shanghai Jiaotong University Children Disease Clinical and Translational Research Center:
   Model and Development focusing on children rare and unknown diseases

6. Career Path Development and Training for Physician-Scientists: Alignment of Competencies for Inter-Professional Education in Clinical and Translational Research
   Dr. Greg Koski, Massachusetts General Hospital, President of the Society of Pharmacology and Medical Research

7. Q & A

Session C: Regulatory sciences to advance translational research and innovative products
Co-chaired by: Dr. FENG Yi, Center for Drug Evaluation, China Food and Drug Administration
Dr. York Tomita, Sr. Advisor for FDA Commissioner Office and Critical Path and Innovation Office

1. CFDA advancing the IND Mechanism and Encourage Translational Research: Bottle-neck with New Drug Innovation
   Dr. FENG Yi, Center for Drug Evaluation, China Food and Drug Administration

2. Better Communication and Collaboration for Better Outcomes
   Dr. York Tomita, Sr. Advisor for FDA Commissioner Office and Critical Path and Innovation Office

3. Industrial partner with Hospital GCP centers: Innovative Collaboration in Translational Research
   Dr. XIA Mingde, Senior Director, Johnson & Johnson Innovation Center

4. Beijing Biobank and medical informatics: Infrastructure and Practice
   Dr. WANG Peng, Director of Beijing Capital Medical University BioBank Project

5. Case study- Deal or Not Deal: Transition of a Cell Therapy Technology to China.
   Dr. Minghao Zheng, Associate Dean of West Australia Univ., Director for Center of Translational Orthopedic Research
6. Pharmacogenetics and Translational Research Experiences in Patient trial studies
   Professor CHEN Xiaoping, Director of Institute of Clinical Pharmacology, China Southern University

7. ISBER Certification: What is the Best Practice of Biobank and Benefit for Translational Research Collaboration
   Dr. Trang Gslier, VP for MyownMed Inc. and formerly FDA Innovation office for Biobank and ISBER standards

8. Chinese Stroke Diseases and Preventions: Translational Research and Outcome Perspectives
   Professor WANG Yongjun, Vice President of Tianjian Hospital, Beijing Capital Medical University

9. Innovation and IP Issue: Key Knowledge and Protections on Translational Research Practice
   Dr. MA Shawn, Director of Alliances and Partnerships, Covidien (China) Medical Devices Technology, Co., Ltd

10. Q & A

Session D: Training physician-scientists and career-path development in translational sciences

Co-chaired by Professor WANG Faqiang, Chair for Chinese Research Hospital Society
Dr. Patrick O’Connor, Chief Internal and General Medicine, Training Program at Yale University

1. Research-oriented Hospital: Promote Translational Research Practice Aims to improve the quality of healthcare service
   Dr. WANG Faqiang, Chairman of Chinese Society for Research-Oriented Hospitals

2. Dr. Patrick O'Connor, Chief Internal and General Medicine, Training Program at Yale University
   Yale University YCCI: Focusing on Training and Education through building up the multidisciplinary mentorship

3. Dr. Amy Huang, International Director for Dean Office at University of Michigan CTSI
   University of Michigan CTSI: What should we do for young physicians during their career development

4. Comparing Clinicians to Basic Researchers: How to Raise up Scientific Question from Their Clinical Practice
   Professor LIU Xiaqiong, Chief Physician of the Dept. of Infectious Diseases at Beijing PUMC Hospital

5. Clinical epidemiology and Clinical research Design Tools
   Professor. WANG Jiyaio, Director, Clinical Epidemiology Resource and Training Center of INCLEN/
   Center of Evidence-based Medicine, Fudan University, Shanghai

6. How we moved from a small number of pilot projects in children health to get to national scale up
   UNICEF China Officer

7. Q & A

Session E: Advanced methodologies and tools in translational research: Drug Induced Liver Injury Issues

Co-chaired by Professor JIA Jidong, Director of GI Dept. Beijing Friendship Hospital, Beijing Capital Medical Univ.
Dr. Paul Watkins, Director of DILI Program at the Hamner-UNC Institute, North Carolina University

1. Building up the Sino-US Collaborative Network on DILI: Pre and Post market Drug Safety and Clinical Applications
   Dr. Paul Watkins, Director of DILI Program at the Hamner-UNC Institute, North Carolina University

2. Comparisons Drug Development (Infectious Disease Drugs): Clinical Review and Practice
   Dr. WANG Tao, Director of Division I at Center for Drug Evaluation (CDE), China FDA

3. Hepatitis C and Liver Cancer: New Drug Translational Research Based on Clinical Therapeutic Evidence
   Professor CHEN Daxi, Deputy Director for Institute of Liver Disease at Beijing YouAn Hospital, Beijing Capital Med Univ.

4. Building up the Platform for monitoring Drug Induced Liver Injury (DILI): Opportunity and Challenge
   Professor Yimin Mao, Shanghai Renji Hospital, GCP Center, Jiaotong Univ. School of Medicine

5. DILI: the Pathology Evidence and Charactizes
   Professor HU Xiqi, the Dept. of Pathology, Huashan Hospital, Shanghai Fudan University

6. Drug Induced Acute Liver Failures
   Professor XIE Qing, Chief of Dept. of Infectious Diseases, Ruijin Hospital, Shanghai Jiaotong University

7. New Drug Development for Liver Diseases
   Professor Xiaohao Xiao, Director for PLA TCM Drug Research Institute, PLA 302 Hospital

8. Q & A

Special Dinner Executive Member Meeting: 18:00-20:00
Advisory Board Meeting for the Sino-American Collaboration on Clinical and Translational Medicine

1. Elect Co-chairs, Executive Members and Secretary-in-General for Advisory Board on the Sino-American Collaboration on CTS
2. Review and Comment on the “2014 - 2018 Five Year Plan” (Draft) for Sino-American Collaboration on CTS projects
3. Review and Comment on the Principles and Recommendation of Clinical and Translational Research and HRP Program
4. Review and Comment on “Clinical and Translational Medicine Awards” Governance and the Rules of Law (draft)
23rd (Sunday) Program
Co-Chaired by Dr. ZENG Yitao and Dr. Robert Califf

Plenary session: Building higher standards in bioethics and HRPP to ensure better outcomes of Translational Research
8:35-9:00  **Plenary speech 8:** The Art of Translational Research: Synchronization of Science Development
Professor ZENG Yitao, Director of Institute of Genetic Diseases, Shanghai Jiaotong Univ. School of Medicine

9:00-9:25  **Plenary speech 9:** Advancing the Collaborations among Academics, Industrials and Regulatory Agencies: Integration of Valuable Resources on Clinical and Translational Research
Dr. Robert Califf, Vice Chancellor and Director of Clinical and Translational Sci. Institute, Duke University

9:25-9:50  **Plenary speech 10:** Building up the Human Research Protection Program in Clinical & Translational Research, Gain the Consensus
Dr. Jeff Cohen, CEO for Human Research Protections Group, formerly Associate Dean for Cornell Univ. SOM

9:50-10:15  **Plenary speech 11:** UNICEF’s views on health research with children as subjects—developing Guidelines and Recommendation
Dr. Robert Scherpier, Chief of Health and Nutrition & Water, Environment and Sanitation

10:15-10:30  **Session speakers in a Panel:** Bring up the Consensus and Developing the Standards
Dr. Tim Shi, Global MD Organization, Board Director and Chief Representative of Global MD China Office
Ms. Tesheia Johnson, Chief Operating Officer, Yale Center for Clinical Investigation, Yale University, SOM

10:15-10:30  **Session speakers in a Panel:** Bring up the Consensus and Developing the Standards
Dr. Tim Shi, Global MD Organization, Board Director and Chief Representative of Global MD China Office
Ms. Tesheia Johnson, Chief Operating Officer, Yale Center for Clinical Investigation, Yale University, SOM

10:30-10:55  **Plenary speech 12:** The Advanced Development on Biochips in Clinical Therapeutics and Diagnosis
Professor CHENG Jing, Tsinghua University and BioCapital Group

10:55-11:20  **Plenary speech 13:** From Basic to Clinic: Stem Cell Model for Traditional Chinese Medicine and Clinical Trials
Dr. Curt I. Civin, Associate Dean for Univ. of Maryland School of Medicine, Director of Stem Cell Res Institute

11:20-11:45  **Plenary speech 14:** Partnering on Methods to Accelerate Drug Development - The C-Path Paradigm
Dr. Martha A. Brumfield, President and CEO of Critical Path Institute, USA

11:45-12:15  **Special report:** Sino-American Collaboration on Clinical & Translational Medicine: Consensus and Recommendation (draft) by the elected chair of the Advisory Committee

12:15-12:30  **Ramp-Up summary:** New Starting-up, New Target and Perspectives in the Near Future
By co-chairs of the SAS-CTM

12:30  **Adjacent**

**AFTERNOON (opinion):**
12:45-14:00  Networking lunch
14:00-15:30  Matching and seeking desired partners and collaborators